Clinical trial · Observational
Detect and Expunge Concealed Tumors of the Liver
Molecular and Immunological Signatures in Recurrent Hepatocellular Carcinoma (HCC)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators long-term goal is to identify molecular and immunological signatures that can be used as biomarkers to accurately predict early recurrence and inform immunotherapeutic strategies in patients with hepatocellular carcinoma (HCC) after hepatectomy. As an initial step toward this long-term investigation, represented by this proposal, the investigators aim to comprehensively and globally describe the patterns of autoantibody expressions, the possible role in disease outcomes, and the relationship between these autoantibodies to tumor-specific/tumor-associated antigens by histologic examination as well as to peripheral immune characteristics in HCC patients with or without recurrence after surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- Early stage HCC
- label
- Compensated cirrhosis
- label
- Chronic hepatitis without cirrhosis
Primary outcomes (1)
- measure
- HCC recurrence diagnosed by dynamic contrast enhanced CT
- timeFrame
- Post-hepatectomy up to 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Provision of signed and dated informed consent form * Collection of biosamples at baseline (sera, liver cancer and non liver cancer tissues, Peripheral blood mononuclear cells (PBMCs)) each of the 3-month interval follow ups (serum and PBMCs) for a total of 4 during the study follow up duration 1 year post-hepatectomy. * Early-stage HCC eligible for hepatectomy for curative intention. Early HCC (Stage A) is limited to a single tumor \<5 cm in diameter or three tumors that are each \<3cm. * Stated willingness to comply with all study procedures and availability for the duration of the study and up to 3 years post-study follow up * Adults aged 18 or older * Both genders and all ethnicities * Willingness to give written, informed consent to be enrolled into the study database * Reside in Vietnam at the time of study and provides contact information (email and/or cell phone number for texting) * No prior or current treatment of HCC * No cancer history within 5 years * No participation in other trial for HCC Treatment * No significant hepatic decompensation * No hepatorenal syndrome * Alpha fetoprotein (AFP) test labs within 90 days irrespective of AFP titer * Two phone numbers and personal identification numbers (CMND number) * No known AIDS related diseases * No significant co-morbid conditions with life expectancy \<2 years Exclusion Criteria: * Individuals who cannot, do not want to, or refused to sign the informed consent form (ICF) * Any serious or active medical or psychiatric illness, which, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol * Documentation was not adequate * Known HIV positive * Taking immunosuppressants * Having any autoimmune diseases based on clinical and/or laboratory availabilities
References
Publications (0)
Data not yet available